Abraxis BioScience, Inc. (NASDAQ: ABII) announced results at ASCO from two ongoing studies evaluating the chemotherapy agent ABRAXANE(R) for Injectable ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE